Publications

Journal Article
Review
Ppublish 533 citations
Electronic publication date
January 13, 2010

View on Pubmed.gov 19555299 | View on doi.org 10.1517/1354378...

Glioblastoma multiforme: a review of where we have been and where we are going.

Search for publications in this journal Expert Opin Investig Drugs - 18(8):1061-83

Abstract

Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal: median survival after diagnosis is about 14 months. Established good prognostic factors are limited, but include young age, high Karnofsky Performance Status (KPS), high mini-mental status examination score, O6-methylguanine methyltransferase promoter methylation, and resection of > 98% of the tumor. Standard treatment includes resection, followed by concurrent chemotherapy and radiotherapy. GBM research is being conducted worldwide at a remarkable pace, with some of the more recent promising studies focused on identification of aberrant genetic events and signaling pathways, tumor stem cell identification and characterization, modulation of tumor immunological responses, combination therapies, and understanding of the rare long-term survivors. Past treatment strategies have failed for various reasons; however, newer strategies in trials today and on the horizon encourage optimism. To help illustrate 'where we have been' with this fatal disease and 'where we are going' with contemporary studies, we include in this review a detailed history of Phase III clinical trials for GBM, with a final emphasis on exciting new treatment strategies that offer hope for future GBM therapy.

References

No references provided.

Cited by 533 citations (total)

Journal Article Research Support, Non-U.S. Gov't

Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.

Electronic publication date March 20, 2012

Search for publications in this journal Nat Neurosci

Timo M Kauer [...] Khalid Shah et al.

Therapeutically engineered stem cells have shown promise for glioblastoma multiforme (GBM) therapy; however, key preclinical studies are urgently needed for...

Journal Article Research Support, Non-U.S. Gov't

A pseudogene-signature in glioma predicts survival.

Electronic publication date March 10, 2016

Search for publications in this journal J Exp Clin Cancer Res

Kai-Ming Gao [...] Yong-Ping You et al.

Pseudogene was recognized as a potential tumor suppressor or oncogene in varies of diseases, however its roles in glioma have...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances